# Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)

> **NCT03633461** · PHASE2 · COMPLETED · sponsor: **Oyster Point Pharma, Inc.** · enrollment: 53 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** OC-02 (simpinicline) nasal spray
- **DRUG:** Placebo (vehicle) nasal spray

## Key facts

- **NCT ID:** NCT03633461
- **Lead sponsor:** Oyster Point Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-14
- **Primary completion:** 2018-09-20
- **Final completion:** 2018-09-20
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2022-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03633461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03633461, "Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03633461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*